Key result
This editorial discusses the TWILIGHT-CKD trial regarding the safety and efficacy of ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention.
Answers are grounded in this paper and cite their sources.
This editorial relates to ‘Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD’, by G.G. Stefanini et al., https://doi.org/10.1093/eurheartj/ehab533. Patients undergoing percutaneous coronary intervention (PCI) for ischaemic heart disease (IHD) are at significant risk of arterial thrombotic events, including stent thrombosis, the threat of which recedes after the procedure upon endothelialization. However, they are also at ongoing risk of atherosclerotic plaque rupture events in the coronary, cerebral, and peripheral vessels, leading to acute coronary syndromes (ACS), stroke, and acute limb ischaemia, respectively, each with an attendant risk of death. Factors that confer a particularly high risk of atherothrombotic events include chronic kidney disease (CKD), particularly in those with an estimated glomerular filtration rate (eGFR) of <60 mL/min and especially when multivessel coronary artery disease is present.1 Though the mechanisms by which CKD confers increased ischaemic risk are not fully established, CKD is...
No takes yet. Share an insight, caveat, or question.
Parker et al. (2021) conducted an editorial in Ischaemic heart disease and chronic kidney disease undergoing percutaneous coronary intervention. Ticagrelor monotherapy was evaluated. This editorial discusses the TWILIGHT-CKD trial regarding the safety and efficacy of ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: